media – Page 32 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

DUPHAT

Organiser: INDEX Conferences & Exhibitions Time：March 24 – March 26, 2026 address：Sheikh Zayed Road, Trade Centre 2 Area, Dubai, United Arab Emirates Exhibition hall：Exhibition Hall: Dubai World Trade Centre Product range: Finished Pharmaceuticals: Various over-the-counter and prescription drugs, different types of traditional Chinese medicines, Western medicines, new drugs, special-effect drugs, biopharmaceuticals, Chinese herbal medicines, raw herbal materials, various bulk pharmaceuticals, chemical pharmaceuticals, pharmaceutical intermediates, medical products, etc. Bulk Pharmaceuticals (Intermediates): Vitamins, hormones, sulfonamides, antipyretic analgesics, tetracyclines, amino acids and their derivatives, chloramphenicols, digestive system drugs, other anti-infective agents, penicillins, aminoglycosides, lincomycins, cardiovascular drugs, antiparasitic drugs, cephalosporins, macrolides, respiratory drugs, central nervous system drugs, and other Western medicine raw materials. Excipients and Dosage Forms: Excipients, glidants, enteric-coating materials, antioxidants, sweeteners, penetration enhancers, preservatives, disintegrants, coating materials, surfactants, opacifiers, flavors, filter aids, stabilizers, lubricants, plasticizers, solvents, flavor correctors, colorants, clarifying agents, pH regulators, and others. Pharmaceutical Technology: Production equipment and technologies for ...
- Source: drugdu
- 104
- October 2, 2025
【EXPERT Q&A】What is the process for CE certification?

Drugdu.com expert’s response: CE certification is a mandatory safety certification for products entering the EU market. Its process aims to ensure that products comply with the basic requirements of the EU’s New Approach to Technical Harmonization and Standardization directives, covering aspects such as safety, health, environmental protection, and consumer protection. Below is a detailed overview of the CE certification process and key points: I. Core Process Steps Determine Applicable Directives and Standards Directive Identification: Based on the product type (e.g., electrical equipment, machinery, medical devices), identify the applicable EU directives, such as: Low Voltage Directive (LVD): Applies to electrical equipment with rated voltages between 50V and 1000V. Electromagnetic Compatibility Directive (EMC): Ensures devices do not interfere with other equipment and are immune to interference. Machinery Directive (MD): Covers all machinery products, including safety components. Standard References: Many directives have corresponding European harmonized standards (EN standards), such as EN 60335 (safety of household ...
- Source: drugdu
- 89
- October 1, 2025
Researchers design factor IX variants for short- and long-term Hemophilia B management

After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, results from a deficiency in coagulation factor IX (FIX), which can lead to prolonged bleeding after injuries or surgery. Thus, patients with hemophilia B are often treated with recombinant FIX as a replacement therapy, and while this approach has improved treatment for hemophilia B, the plasma half-lives of the approved products are only about 3-4 days, and frequent injections are needed. Consequently, there is a pressing need for recombinant FIX products with enhanced plasma half-life that allows less frequent dosing. In the current study, the laboratories of Professor Jan Terje Andersen at the University of Oslo and Alessio Branchini/Mirko Pinotti at the University of Ferrara (Italy) present design and characterization of long-acting human albumin-fused FIX variants, each exhibiting unique pharmacokinetic properties. The ...
- Source: drugdu
- 90
- September 30, 2025
FDA Approves Opzelura for Atopic Dermatitis in Children

By Lori Solomon HealthDay ReporterMONDAY, Sept. 29, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD). The approval is the first topical Janus kinase (JAK) inhibitor for the short-term, noncontinuous chronic treatment of mild-to-moderate AD in nonimmunocompromised children (age 2 years and older) whose disease is not well controlled with topical prescription therapies or when topical therapies are not recommended. The approval is based on results from the phase 3 TRuE-AD3 trial, which evaluated the safety and efficacy of Opzelura cream in children ages 2 to <12 years with AD. The primary end point was met, with significantly more patients treated with Opzelura achieving Investigator’s Global Assessment-treatment success versus patients treated with vehicle control cream. The trial also met the secondary end point of more Opzelura-treated patients demonstrating ≥75 percent improvement ...
- Source: drugdu
- 121
- September 30, 2025
Lunan Pharmaceutical’s blockbuster first generic drug approved, ushering in changes in the allergy market

Recently, the official website of the State Food and Drug Administration announced that the orally disintegrating tablets of Bilastine, which were submitted by Shandong Xinshidai Pharmaceutical, a subsidiary of Lunan Pharmaceutical Group, under the Class 3 chemical drug registration classification, have been approved for marketing and are deemed to have passed the generic drug quality and efficacy consistency evaluation. They are used for the symptomatic treatment of urticaria in adults and adolescents (12 years and above). The original product, Bilastine, was developed by FAES Pharmaceuticals of Spain and first marketed in the EU in August 2010. In June 2023, Menarini’s Bilastine tablets were approved for marketing in China. In 2024, Jiangsu Huayang Pharmaceutical secured the first domestic generic version of Bilastine tablets. This time, Lunan Pharmaceutical’s Bilastine orally disintegrating tablets were approved for marketing, marking the first domestic generic version of this dosage form and the first to pass review. ...
- Source: drugdu
- 103
- September 30, 2025
A subsidiary received approval for clinical trials of HRS-2129 tablets. Currently, no drug with the same target has been approved for marketing in China.

According to the AI news of the China Business Network, on September 29, Hengrui Medicine (600276.SH) announced that its subsidiaries Shandong Shengdi Pharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration for HRS-2129 tablets, agreeing to conduct clinical trials for the indications of adult diabetic peripheral neuropathy pain and adult osteoarthritis pain. HRS-2129 tablets are intended for the treatment of acute and chronic pain. Currently, no drugs with the same target have been approved for marketing in China. As of now, the cumulative R&D investment in this project is approximately 112 million yuan. According to relevant laws and regulations, after obtaining the drug clinical trial approval notice, the drug must still conduct clinical trials and be reviewed and approved by the National Medical Products Administration before it can be produced and marketed. https://finance.eastmoney.com/a/202509293526362066.html
- Source: drugdu
- 160
- September 30, 2025
API China

Organiser: Sinopharm Reed Exhibitions Time：November 12 – November 14, 2025 address：No. 66 Yuelai Avenue, Yubei District, Chongqing, China Exhibition hall：Chongqing International Expo Center Product range: Pharmaceutical APIs (Active Pharmaceutical Ingredients), pharmaceutical excipients, natural extracts, chemical reagents, intermediates, fine chemical raw materials, key raw materials, food ingredients and additives, veterinary drug raw materials, feed ingredients and additives, health product ingredients and additives, biotechnology, pharmaceutical R&D services, contract custom manufacturing services, registration and pharmaceutical affairs services, training services. About API China ： As the longest-running exhibition in China’s pharmaceutical sector, the China International Pharmaceutical APIs Expo (API China) was first held in 1968. The exhibition showcases not only over 50,000 types of APIs across 24 major categories but also encompasses all excipients, functional ingredients, inner and outer packaging materials, as well as production and testing equipment required for the manufacturing of pharmaceuticals and health products.
- Source: drugdu
- 86
- September 30, 2025
Eli Lilly’s new drug Inluriyo has been approved by the US FDA for the treatment of advanced or metastatic breast cancer

Recently, Eli Lillyannounced that the U.S. Food and Drug Administration (FDA) has approved its oral estrogen receptor antagonist Inluriyo (imlunestrant, 200 mg tablets) for the treatment of adult patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease has progressed after at least one line of endocrine therapy (ET). https://finance.eastmoney.com/a/202509283525492454.html
- Source: drugdu
- 100
- September 29, 2025
New specifications of sitagliptin and metformin extended-release tablets approved

　　Xuantai PharmaceuticalOn September 26, the company announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., received the “Notice of Approval of Supplementary Drug Application” from the National Medical Products Administration (NMPA). The NMPA approved the company’s supplemental application for sitagliptin and metformin extended-release tablets to include 50 mg of sitagliptin phosphate (calculated as CHFNO3) and 500 mg of metformin hydrochloride per tablet. Currently marketed, the dosage form contains 50 mg of sitagliptin phosphate (calculated as CHFNO3) and 1000 mg of metformin hydrochloride per tablet. This newly approved dosage form will help better meet patient needs, enhance product competitiveness and market share, and positively impact the company’s future performance. https://finance.eastmoney.com/a/202509263524765181.html
- Source: drugdu
- 84
- September 29, 2025
Based on the logic of prosperity and industry trends, public fundraising explores advantages, styles, and opportunities for “diffusion”

Since the Federal Reserve cut interest rates in September, the technology growth style of the A-share market has continued to strengthen. As of September 26th, several semiconductor equipment related themed ETFs have performed well. Industry institutions analyze that new developments in the artificial intelligence (AI) industry are constantly emerging, and the structural market driven by growth styles is still ongoing. However, with the “pre holiday effect” of the National Day holiday, if there is no significant positive catalyst, the market may be mainly volatile in the near future. At the same time as the valuation of the technology sector enters a high level, the internal rotation of the sector is also accelerating. Industry institutions suggest that the previous extreme structural differentiation and overly concentrated consensus in the market need to be digested and consolidated. In the current market driven by incremental funds and the prosperity of some industries, rotation is ...
- Source: drugdu
- 98
- September 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.